Skip to content

Vir Biotechnology

US · VIR #2824 by market cap Listed 2019
8.39 -0.48 -5.41%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

About Vir Biotechnology

Vir Biotechnology, Inc. operates as a clinical-stage immunology company that focuses on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. The firm's technology platforms include antibody, T cell, innate immunity and siRNA, which are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. The company was founded by Robert Taylor Nelsen, Klaus Frueh, Jay Parrish, Lawrence Corey, and Louis Picker in April 7, 2016 and is headquartered in San Francisco, CA.

Founded
2016
CEO
Dr. Marianne De Backer, M.B.A.,M.Sc.,PhD
Employees
367
Headquarters
San Francisco, California, United States of America
Fiscal year end
12-31
Website
vir.bio

Company profile

Exchange
US
Symbol
VIR
Market-cap rank
#2824
Listing date
2019-10-11
Market cap
1.56B
Float cap
1.31B
Shares out
186.27M
Float shares
156.08M

Sectors & themes

Biotechnology Fractional Shares JP

Browse all sectors & themes

Quote time 2026-11-20 19:30:05 · For reference only, not investment advice and not tailored to your situation.

Vir Biotechnology discussion 0 comments

Add a comment